Lacosamid Glenmark (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: adjunctive therapy that reduces seizure frequency in epilepsy patients.
• Focal epilepsy: improves seizure control when added to existing antiepileptic regimens.
• Epilepsy (adjunctive therapy): contributes to overall seizure management as part of combination treatment.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes and thereby diminishing the propagation of abnormal electrical activity that underlies seizure generation.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Nausea: mild gastrointestinal upset.
• Fatigue: increased tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Somnolence: tendency to feel sleepy.
• Diplopia: occasional double vision.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Toxic epidermal necrolysis: life‑threatening skin detachment.
• Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing heart disease.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Severe hepatic injury: marked liver enzyme elevation or failure.
• Anaphylaxis: rare allergic reaction with respiratory compromise.

When prescribing Lacosamide, clinicians should consider several safety aspects.

• Renal impairment: monitor renal function and adjust dose if needed.
• Hepatic impairment: use with caution and observe liver enzymes.
• Pregnancy: risk unknown; prescribe only if benefits outweigh potential fetal risks.
• Concomitant antiepileptics: assess for additive CNS depression or altered plasma levels.
• Driving and operating machinery: advise patients about possible dizziness or somnolence.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Lacosamide exposure.
• Strong CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic levels.
• Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: Lacosamide may lower hormonal efficacy.
• Certain antidepressants (e.g., SSRIs): potential for serotonin syndrome.
• Alcohol: may enhance central nervous system depression.